Journal of Cancer Research and Therapeutics Close
 

Figure 3: The association between OS of patients and the number of chemotherapy cycles. Two hundred fifty-three patients were followed up for OR. The median OS was 473 days. The Kaplan-Meier survival analysis and log-rank test were performed to examine the correlation between OS of patients and the number of chemotherapy cycles. The blue curve indicates <4 chemotherapy cycles, while the green curve indicates ≥4 chemotherapy cycles. The OS in 97 patients with ≥4 chemotherapy cycles was significantly longer than for 156 patients with <4 chemotherapy cycles (log-rank test, P = 0.030)

Figure 3: The association between OS of patients and the number of chemotherapy cycles. Two hundred fifty-three patients were followed up for OR. The median OS was 473 days. The Kaplan-Meier survival analysis and log-rank test were performed to examine the correlation between OS of patients and the number of chemotherapy cycles. The blue curve indicates <4 chemotherapy cycles, while the green curve indicates ≥4 chemotherapy cycles. The OS in 97 patients with ≥4 chemotherapy cycles was significantly longer than for 156 patients with <4 chemotherapy cycles (log-rank test, <i>P</i> = 0.030)